WuXi XDC Cayman Inc. (HKG:2268)
72.10
-0.95 (-1.30%)
Sep 11, 2026, 4:08 PM HKT
WuXi XDC Cayman Revenue
WuXi XDC Cayman had revenue of 3.70B CNY in the half year ending June 30, 2026, with 122.28% growth. This brings the company's revenue in the last twelve months to 6.94B, up 36.49% year-over-year. In the year 2025, WuXi XDC Cayman had annual revenue of 5.94B with 46.69% growth.
Revenue (ttm)
6.94B CNY
Revenue Growth
+36.49%
P/S Ratio
11.54
Revenue / Employee
1.91M CNY
Employees
3,628
Market Cap
92.51B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.94B | 1.89B | 46.69% |
| Dec 31, 2024 | 4.05B | 1.93B | 90.80% |
| Dec 31, 2023 | 2.12B | 1.13B | 114.44% |
| Dec 31, 2022 | 990.42M | 679.29M | 218.33% |
| Dec 31, 2021 | 311.13M | 214.78M | 222.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Adicon Holdings | 3.06B |
| Kindstar Globalgene Technology | 1.10B |
| Yunkang Group | 624.49M |
| Mega Genomics | 413.73M |
| Biosino Bio-Technology and Science Incorporation | 196.98M |
| Zhong Ji Longevity Science Group | 150.07M |
| King International Investment | 143.23M |
| Guanze Medical Information Industry (Holding) | 98.16M |
WuXi XDC Cayman News
- 16 days ago - WuXi XDC Cayman Earnings Call Transcript: H1 2026 - Transcripts
- 16 days ago - WuXi XDC Cayman Earnings release: H1 2026 - Filings
- 16 days ago - WuXi XDC Cayman Slides: H1 2026 - Filings
- 5 months ago - Akari Therapeutics Announces Strategic Partnership With WuXi XDC - Nasdaq
- 5 months ago - WuXi XDC Cayman Earnings Call Transcript: H2 2025 - Transcripts
- 5 months ago - WuXi XDC Cayman Earnings release: H2 2025 - Filings
- 5 months ago - WuXi XDC Cayman Slides: H2 2025 - Filings
- 5 months ago - WuXi XDC Cayman Annual report: H2 2025 - Filings